stay updated with our newsletter

Subscribe
Facebook Twitter Linkedin

Beyond Immunity: How Echinacea EP107 Targets Stress and Anxiety

Stress and anxiety have reached epidemic proportions, affecting millions of Americans. Recent data shows 55 to 65 percent of U.S. adults experience significant daily stress, and almost 20 percent live with an anxiety disorder, with devastating impacts on overall health. While conventional approaches are lacking and limited, emerging research points to an unexpected ally for mental harmony: a specialized echinacea extract known as EP107, shown to safely lessen stress and ease anxiety.

 

Modern Life and Its Troubling Consequences

In our contemporary, always-on culture that views intensity as a virtue and rest as a luxury, the toll on health and well-being is both immediate and enduring. Relentless work schedules, family demands, financial insecurity, and digital overload fuel stress and burnout. Lifestyle and environmental factors—including poor eating habits, exposure to pollution and chemicals, excessive caffeine use, and sedentary behaviors—further amplify anxiety. What’s more, these varied influences exist in a complex relationship with each other that complicates treatment. For example, blue light from devices alters circadian rhythms and interferes with sleep, which exacerbates stress. Meanwhile, a poor diet damages gut fitness and compromises the microbiota-gut-brain axis, creating a self-reinforcing cycle of exhaustion, mental strain, and pervasive tension. 1, 2, 3, 4, 5

In the short term, chronic, unresolved stress disrupts emotional balance and significantly diminishes quality of life. ”On a daily level, patients experience this as a loss of resilience,” says Gaetano Morello, ND, board-certified naturopathic doctor. ”Mentally, it presents as irritability, anxiety, poor focus, and racing thoughts. Physically, we see fatigue, sleep disruption, muscle tension, headaches, and changes in appetite. Behaviorally, productivity declines, relationships become strained, and individuals begin relying on compensatory mechanisms like caffeine, sugar, and at times alcohol.”

But the deeper concern is what happens over time—the cumulative stress burden that leads to long-term health consequences. ”This can show up as cardiovascular strain, metabolic dysfunction, immune dysregulation, chronic low-grade inflammation, and a significantly higher risk of depression and burnout,” says Morello. Prolonged stress and anxiety are implicated in the development and progression of cancer, diabetes, cardiovascular disease, neurodegenerative disorders, and other diseases, and research links chronic stress with higher mortality. 6, 7, 8, 9, 10, 11

Conventional medicine has few answers beyond pharmaceutical treatments—a reactive model that prioritizes rapid symptom relief over root-cause interventions. But drugs like benzodiazepines are associated with a variety of adverse effects, ranging from sedation, memory impairment, and respiratory depression to severe physical dependence or addiction. Furthermore, mainstream solutions fail to address the underlying origins of persistent stress, including nutritional deficiencies, lack of exercise, and emotional dysregulation. Without resolving core imbalances, the conventional approach remains limited to masking symptoms—not promoting systemic recovery.

Help your patients navigate stress and anxiety with our Stress Management Resource Center, a collection of our most popular articles and practitioner-focused strategies for stress, including Simplified Stress Management Protocol and Magnolia Bark for Mental Health and Stress Support.

Natural Interventions for Comprehensive Stress Support

A large and growing body of research demonstrates the efficacy of specific diet and lifestyle modifications in managing stress, and certain botanicals and supplements have been shown to soothe tension and anxiety, recalibrate physiology, and ease depression resulting from chronic stress. Some highlights:

  • Diet and nutrition. Modern diets are definitely linked with heightened stress and anxiety. Excessive sugar, ultra-processed foods, and low-quality oils fuel neuroinflammation and mood disturbances. Deficiencies in key nutrients disrupt neurotransmitter production and impair emotional regulation, increasing biological strain and degrading sleep. The typical Western diet also compromises gut health, further decreasing stress resilience. Conversely, research consistently shows that whole, nutrient-dense foods foster a diverse and thriving gut ecosystem, promoting restorative sleep and reducing stress and anxiety. 12, 13, 14, 15, 16
  • Exercise and physical movement. Sedentary lifestyles create a self-perpetuating pattern of stress and fragmented sleep, and studies show regular movement relieves tension, supports restful slumber, and improves emotional balance. Physical activity modulates cortisol levels and stabilizes mood, and even short bursts of aerobic exercise significantly lessen anxiety sensitivity. Along with high-intensity workouts, contemplative practices like yoga, tai chi, and qi gong soothe the sympathetic nervous system, lowering cortisol and heart rate and promoting peace. 17, 18, 19, 20, 21, 22, 23
  • Sleep optimization. Chronic sleep deprivation directly correlates with increased anxiety and diminished resistance to stress. The absence of deep, restful slumber spikes cortisol, impairing emotional equilibrium and magnifying sensitivity to everyday triggers. Heightened anxiety and stress interfere with sleep, driving an ongoing negative cycle. Through a powerful combination of hormonal regulation and neurological resetting, uninterrupted sleep acts as a biological buffer, preventing daily pressures from spiraling into anxiety and stress.24, 25, 26, 27, 28
  • Meditation and mindfulness. While deep sleep naturally recalibrates amygdala activity, mindfulness practices train the emotional brain toward more adaptive, measured responses during waking hours.  Mindfulness-Based Stress Reduction (MBSR) has been shown to dampen amygdala reactivity and enhance functional connectivity with the prefrontal cortex—a shift that encourages emotional flexibility and lessens stress. The effects are profound: in one trial, mindfulness meditation worked as well as pharmaceutical interventions for treating anxiety disorders.29, 30, 31, 32
  • Supplements and botanicals. Research continues to confirm the effectiveness of natural supplements for safely easing stress and anxiety. Several studies demonstrate L-theanine’s ability to boost calming neurotransmitters and promote relaxation, without sedation. And botanicals like passionflower, valerian, lemon balm, lavender, and chamomile are widely recognized for their tension-taming, stress-reducing properties.33, 34, 35, 36, 37, 38

Though many of these botanicals are useful, they’re limited by potential medication interactions and a slower onset of action. More importantly, they don’t address the core causes of stress. Adaptogens like ashwagandha and rhodiola work differently, supporting the body’s natural ability to adapt, increasing resilience, and maintaining equilibrium. In research, ashwagandha has been shown to decrease brain markers of anxiety, enhance stress resistance, and improve quality of life and well-being. Rhodiola’s cortisol-blunting, mood-balancing properties are also widely documented, with research linking rhodiola treatment with lower stress, anxiety, and depression. When taken together, ashwagandha and rhodiola work synergistically to provide even greater benefits.39, 40, 41, 42, 43, 44, 45, 46

The most compelling research, however, centers on a specialized extract from echinacea—EP107, a clinically tested botanical shown to quickly ease stress and anxiety, with no adverse effects.

What Makes Echinacea EP107 So Compelling

Echinacea is typically associated with immune support. But not all echinacea extracts are equal.” EP107 is a standardized hydroalcoholic root extract of Echinacea angustifolia, specifically developed for its effects on the nervous system rather than immunity,” says Morello. While traditional echinacea products (often E. purpurea) are standardized to compounds like polysaccharides, EP107 is standardized to a specific alkamide fingerprint, along with echinacoside.

”These alkamides are the key,” Morello says. ”What makes EP107 unique is its multi-site cultivation and blending strategy. Extracts are sourced from plants grown in ten different locations, then carefully combined to create a consistent and reproducible alkamide profile. This is critical, as variations in growing conditions can dramatically alter the biochemical composition, sometimes even producing compounds that counteract desired effects.”

Careful cultivation and processing methods used in producing EP107 ensure the extract is free from industrial contamination, pesticides, or herbicides. The roots are harvested and dried in a manner that preserves their biochemical structure, and hexane-free extraction processes maintain the delicate alkamide profile. The final product then undergoes rigorous testing for purity, including heavy metals, pesticides, and microbial contamination.

What makes EP107 particularly compelling is how it interacts with the endocannabinoid system. ”The alkamides found in EP107 are structurally similar to anandamide, the body’s endogenous ‘bliss molecule,’” Morello says. ”This similarity allows them to influence the ECS in two key ways. First, they can bind to CB1 receptors in the brain, particularly in areas like the amygdala, which plays a central role in fear and anxiety processing. This helps modulate the stress response in a way that promotes calm without impairing cognition.”

Second, these compounds inhibit FAAH, the enzyme responsible for breaking down anandamide. ”By slowing this degradation, endogenous anandamide levels increase, prolonging its calming and mood-stabilizing effects,” says Morello. ”The net effect is a balanced, non-sedating anxiolytic response, without the drawbacks of conventional sedatives or dependency-forming agents.”47, 48, 49, 50, 51, 52

Earlier animal models found EP107 decreased anxiety-like behavior, increased exploration and social interactions, and reduced stress-induced social avoidance and conditioned fear. Even at low doses, the effects were comparable to the benzodiazepine chlordiazepoxide and the selective serotonin reuptake inhibitor fluoxetine, with no locomotor suppressant activities. Human research validates the ability of EP107 to minimize stress and anxiety, safely and rapidly—often in as little as one day. 53, 54

In one double-blind, placebo-controlled trial, participants who scored above 45 points on the state or on the trait subscale of the State Trait Anxiety Inventory (STAI) received either EP107 or a placebo. The EP107 group showed significantly lower anxiety scores than those in the placebo group. In another study, EP107 reduced stress and anxiety in volunteers with high STAI scores within three days, with effects remaining stable for the seven-day duration of the trial, and for the two weeks that followed treatment.55, 56

Clinical research suggests EP107 specifically targets psychic symptoms of anxiety—including worry, fear, and insecurity—rather than somatic symptoms like muscle tension. A placebo-controlled, double-blind study found EP107 extract significantly alleviated anxiety and was superior to placebo in three psychic anxiety items, pointing to its potential usefulness in mild or early-phase anxiety when somatic symptoms are not prominent. In addition to its anxiolytic properties, longer-term studies of six weeks suggest EP107’s antidepressant benefits. In a double-blind, randomized controlled trial, adults who received EP107 had significant improvements in positive affect and emotional well-being compared to placebo, hinting at its promising role in alleviating stress-induced depression. 57, 58, 59, 60

In addition to being fast-acting and effective, research confirms EP107 is well tolerated, with no reported daytime drowsiness or mental fogginess. And unlike conventional medications, EP107 eases stress and anxiety without sedation, cognitive impairment, or the risk of physical dependence.

Other Evidence-Based Botanicals

Other science-backed herbs—particularly saffron and curcumin—have been shown to relieve mood imbalances and emotional disturbances resulting from relentless stress, without adverse reactions:

  • Bioactive compounds in saffron appear to inhibit reuptake of mood-regulating neurotransmitters in much the same way as conventional antidepressants like SSRIs. Additionally, its well-documented antioxidant and anti-inflammatory properties minimize neuroinflammation, and in clinical trials, saffron’s effectiveness in treating mild to moderate depression was comparable to that of standard medications like fluoxetine. 61, 62, 63, 64, 65
  • Curcumin, particularly as highly bioavailable BCM-95, works primarily by modulating neurotransmitters, lowering cortisol, and blunting neuroinflammation. Emerging research shows curcumin also improves the microbiome and strengthens the intestinal barrier, and some studies suggest it’s comparable to pharmaceutical antidepressants. Like ashwagandha and rhodiola, saffron and curcumin have synergistic activities when taken together, measurably enhancing the effects of each.66, 67, 68, 69, 70

 

References

  1. Ellingson LD et al. Changes in sedentary time are associated with changes in mental well-being over 1 year in young adults. Prev Med Rep. 2018 Jul 30;11:274-281.
  2. Bremner JD et al. Diet, Stress, and Mental Health. Nutrients. 2020 Aug 13;12(8):2428.
  3. Devi KA, Singh SK. The hazards of excessive screen time: Impacts on physical health, mental health, and overall well-being. J Educ Health Promot. 2023 Nov 27;12:413.
  4. Zhong C et al. Electronic Screen Use and Sleep Duration and Timing in Adults. JAMA Netw Open. 2025 Mar 3;8(3):e252493.
  5. Madison A, Kiecolt-Glaser JK. Stress, depression, diet, and the gut microbiota: human-bacteria interactions at the core of psychoneuroimmunology and nutrition. Curr Opin Behav Sci. 2019 Aug;28:105-110.
  6. Garg RK. The alarming rise of lifestyle diseases and their impact on public health: A comprehensive overview and strategies for overcoming the epidemic. J Res Med Sci. 2025 Jan 30;30:1.
  7. Rohleder N. Stress and inflammation – The need to address the gap in the transition between acute and chronic stress effects. Psychoneuroendocrinology. 2019 Jul;105:164-171.
  8. Liu YZ et al. Inflammation: The Common Pathway of Stress-Related Diseases. Front Hum Neurosci. 2017 Jun 20;11:316.
  9. Mariotti A. The effects of chronic stress on health: new insights into the molecular mechanisms of brain-body communication. Future Sci OA. 2015 Nov 1;1(3):FSO23.
  10. Cohen S et al. Psychological stress and disease. JAMA. 2007 Oct 10;298(14):1685-7.
  11. Tian F et al. Association of stress-related disorders with subsequent risk of all-cause and cause-specific mortality: A population-based and sibling-controlled cohort study. Lancet Reg Health Eur. 2022 May 28;18:100402.
  12. Sarris J et al. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry. 2015;2:271–274
  13. Jacka FN et al. Association of Western and traditional diets with depression and anxiety in women. Am J Psychiatry.  2010;167:305–311
  14. Kris-Etherton PM et al. Nutrition and behavioral health disorders: depression and anxiety. Nutr Rev. 2021 Feb 11;79(3):247-260.
  15. Ikonte CJ et al. Micronutrient Inadequacy in Short Sleep: Analysis of the NHANES 2005-2016. Nutrients. 2019 Oct 1;11(10):2335.
  16. Bear TLK et al. The Role of the Gut Microbiota in Dietary Interventions for Depression and Anxiety. Adv Nutr. 2020 Jul 1;11(4):890-907.
  17. Smits JA et al. Reducing anxiety sensitivity with exercise. Depress Anxiety. 2008;25(8):689-99.
  18. Anderson E, Shivakumar G. Effects of exercise and physical activity on anxiety. Front Psychiatry. 2013 Apr 23;4:27.
  19. Broman-Fulks JJ, Storey KM. Evaluation of a brief aerobic exercise intervention for high anxiety sensitivity. Anxiety Stress Coping. 2008 Apr;21(2):117-28.
  20. Xie Y et al. Effects of Exercise on Sleep Quality and Insomnia in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Psychiatry. 2021 Jun 7;12:664499.
  21. Alnawwar MA et al. The Effect of Physical Activity on Sleep Quality and Sleep Disorder: A Systematic Review. Cureus. 2023 Aug 16;15(8):e43595.
  22. Chen KW et al. Meditative therapies for reducing anxiety: a systematic review and meta-analysis of randomized controlled trials. Depress Anxiety. 2012 Jul;29(7):545-62.
  23. Zou L et al. Effects of Mind⁻Body Exercises (Tai Chi/Yoga) on Heart Rate Variability Parameters and Perceived Stress: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. J. Clin. Med. 2018;7:404.
  24. Richards A et al. Sleep disturbance in PTSD and other anxiety-related disorders: an updated review of clinical features, physiological characteristics, and psychological and neurobiological mechanisms. Neuropsychopharmacology. 2020 Jan;45(1):55-73.
  25. Palmer CA et al. Sleep loss and emotion: A systematic review and meta-analysis of over 50 years of experimental research. Psychol Bull. 2024 Apr;150(4):440-463.
  26. Blackwelder A et al. Effect of Inadequate Sleep on Frequent Mental Distress. Prev Chronic Dis 2021;18:200573.
  27. Goldstein AN et al. Tired and apprehensive: anxiety amplifies the impact of sleep loss on aversive brain anticipation. J Neurosci. 2013 Jun 26;33(26):10607-15.
  28. Kalmbach DA et al. Insomnia symptoms and short sleep predict anxiety and worry in response to stress exposure: a prospective cohort study of medical interns. Sleep Med. 2019 Mar;55:40-47.
  29. Hoge EA et al. Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2023 Jan 1;80(1):13-21.
  30. Chiesa A, Serretti A. Mindfulness-based stress reduction for stress management in healthy people: a review and meta-analysis. J Altern Complement Med. 2009 May;15(5):593-600.
  31. Goldin PR, Gross JJ. Effects of mindfulness-based stress reduction (MBSR) on emotion regulation in social anxiety disorder. Emotion. 2010 Feb;10(1):83-91.
  32. Evans S et al. Mindfulness-based cognitive therapy for generalized anxiety disorder. J Anxiety Disord. 2008 May;22(4):716-21.
  33. Hidese S et al. Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. Nutrients. 2019 Oct 3;11(10):2362.
  34. Janda K et al. Passiflora incarnata in Neuropsychiatric Disorders: A Systematic Review. Nutrients. 2020 Dec 19;12(12):3894.
  35. Shinjyo N et al. Valerian Root in Treating Sleep Problems and Associated Disorders: A Systematic Review and Meta-Analysis. J Evid Based Integr Med. 2020 Jan-Dec;25:2515690X20967323
  36. Ghazizadeh J et al. The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta-analysis. Phytother Res. 2021 Dec;35(12):6690-6705.
  37. Yoo O, Park SA. Anxiety-Reducing Effects of Lavender Essential Oil Inhalation: A Systematic Review. Healthcare (Basel). 2023 Nov 17;11(22):2978.
  38. Saadatmand S et al. The Effect of Oral Chamomile on Anxiety: A Systematic Review of Clinical Trials. Clin Nutr Res. 2024 Apr 23;13(2):139-147.
  39. Singh N et al. An overview on Ashwagandha: a rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011; 8(5 Suppl): 208–213.
  40. Mishra LC et al. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000 Aug;5(4):334-46.
  41. Chandrasekhar K et al. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012 Jul;34(3):255-62.
  42. Auddy B et al. A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: A double-blind, randomized, placebo-controlled study. J Am Nutraceutical Assoc. 2008;11:50–6.
  43. Khanum F et al. Rhodiola rosea: A Versatile Adaptogen. Compr Rev Food Sci Food Saf. 2005 Jul;4(3):55-62.
  44. Ivanova Stojcheva E, Quintela JC. The Effectiveness of Rhodiola rosea L. Preparations in Alleviating Various Aspects of Life-Stress Symptoms and Stress-Induced Conditions-Encouraging Clinical Evidence. Molecules. 2022 Jun 17;27(12):3902.
  45. Anghelescu IG et al. Stress management and the role of Rhodiola rosea: a review. Int J Psychiatry Clin Pract. 2018 Nov;22(4):242-252.
  46. Bystritsky A et al. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 2008 Mar;14(2):175-80.
  47. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63.
  48. Petrie GN et al. Endocannabinoids, cannabinoids, and the regulation of anxiety. Neuropharmacology. 2021 Sep 1;195:108626.
  49. Woelkart K et al. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Med. 2005 Aug;71(8):701-5.
  50. Jedlinszki N et al. Possible Role of Fat Tissue in the Pharmacokinetics of Dodeca-2E, 4E, 8Z, 10E/Z- tetraenoic Acid Isobutylamides after Oral Administration of Echinacea angustifolia Extract in Rats. Natural Products Communications, Volume 9 Issue 6:737-888.
  51. Hájos N et al. The Effects of an Echinacea Preparation on Synaptic Transmission and the Firing Properties of CA1 Pyramidal Cells in the Hippocampus. Phytother Res. 2012 Mar;26(3):354-62.
  52. Hohmann J et al. Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors. Phytochemistry. 2011 Oct;72(14-15):1848-53.
  53. Haller J et al. The effect of Echinacea preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide. Phytother Res. 2010 Nov;24(11):1605-13.
  54. Haller J et al. The anxiolytic potential and psychotropic side effects of an echinacea preparation in laboratory animals and healthy volunteers. Phytother Res. 2013 Jan;27(1):54-61.
  55. Haller J et al. Double-blind placebo-controlled trial of the anxiolytic effects of a standardized Echinacea extract. Phytother Res. 2020 Mar;34(3):660-668.
  56. Haller J et al. The anxiolytic potential and psychotropic side effects of an echinacea preparation in laboratory animals and healthy volunteers. Phytother Res. 2013 Jan;27(1):54-61.
  57. Haller J et al. The Effects of Echinacea (EP107TM) on Anxiety: A Comparison of Anxiety Measures in a Randomized, Double Blind, Placebo-Controlled Study. Pharmaceuticals (Basel). 2025 Feb 17;18(2):264.
  58. Lopresti AL, Smith SJ. An investigation into the anxiety-relieving and mood-enhancing effects of Echinacea angustifolia (EP107™): A randomised, double-blind, placebo-controlled study. J Affect Disord. 2021 Oct 1;293:229-237.
  59. Ross RA et al. The Role of Chronic Stress in Anxious Depression. Chronic Stress (Thousand Oaks). 2017 Feb 17;1:2470547016689472.
  60. Malykhin N et al. Effects of duration and intensity of psychological stressors on mental health outcomes. J Psychiatr Res. 2025 Jul;187:211-222.
  61. Chauhan S et al. Exploring the Potential of Saffron as a Therapeutic Agent in Depression Treatment: A Comparative Review. Yale J Biol Med. 2024 Sep 30;97(3):365-381.
  62. Siddiqui MJ et al. Saffron (Crocus sativus L.): As an Antidepressant. J Pharm Bioallied Sci. 2018 Oct-Dec;10(4):173-180.
  63. Bian Y et al. Neuroprotective Potency of Saffron Against Neuropsychiatric Diseases, Neurodegenerative Diseases, and Other Brain Disorders: From Bench to Bedside. Front Pharmacol. 2020 Oct 6;11:579052.
  64. Bian Y, Zhao C, Lee SM. Neuroprotective Potency of Saffron Against Neuropsychiatric Diseases, Neurodegenerative Diseases, and Other Brain Disorders: From Bench to Bedside. Front Pharmacol. 2020 Oct 6;11:579052.
  65. Khaksarian M et al. The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine in treating depression: a systematic review and meta-analysis. Psychol Res Behav Manag. 2019 Apr 23;12:297-305.
  66. Lopresti AL. Potential Role of Curcumin for the Treatment of Major Depressive Disorder. CNS Drugs. 2022 Feb;36(2):123-141.
  67. Yuan J et al. Potential therapeutic benefits of curcumin in depression or anxiety induced by chronic diseases: a systematic review of mechanistic and clinical evidence. Front Pharmacol. 2025 Aug 22;16:1638645.
  68. Al-Karawi D et al. The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials. Phytother Res. 2016 Feb;30(2):175-83.
  69. Ramaholimihaso T et al. Curcumin in Depression: Potential Mechanisms of Action and Current Evidence-A Narrative Review. Front Psychiatry. 2020 Nov 27;11:572533.
  70. Lopresti AL et al. Curcumin for the treatment of major depression: a randomised, double-blind, placebo-controlled study. J Affect Disord. 2014;167:368-75.

 

Related Articles